Biogen Australia

The Australian affiliate markets AVONEX® (interferon beta-1a), TYSABRI® (natalizumab), TECFIDERA® (dimethyl fumarate), PLEGRIDY® (peginterferon beta-1a) and ZINBRYTA® (daclizumab), which are registered and reimbursed for Relapsing Remitting Multiple Sclerosis (RRMS). FAMPYRA® (fampridine) is used to improve walking ability in adults with Multiple Sclerosis.

The Company

Biogen is one of the world’s leading biotechnology companies, with a focus on developing therapies for neurological, autoimmune and rare diseases.